CD274 and cancer: Furthermore, blocking programmed death ligand-1 (PD-L1) on cancer cells reduces their glycolysis rate by inhibition of mTOR-related pathways, which would permit T-cells to exploit their glycolytic capacity and restore IFN-γ production (26).